How should donepezil be started and titrated for a 78-year-old patient with worsening Alzheimer’s dementia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Start and Titrate Donepezil for Alzheimer's Dementia

Start donepezil at 5 mg once daily in the evening, just before bedtime, and increase to 10 mg once daily after 4 to 6 weeks if tolerated. 1

Initial Dosing

  • Starting dose: 5 mg once daily in the evening, just prior to retiring 2, 1
  • Can be taken with or without food, though taking with food reduces gastrointestinal side effects (nausea, vomiting, diarrhea) 2
  • Once-daily dosing provides excellent convenience and adherence compared to other cholinesterase inhibitors 2

Titration Schedule

For mild to moderate Alzheimer's disease:

  • Maintain 5 mg daily for 4 to 6 weeks before considering dose increase 2, 1
  • After 4-6 weeks, increase to 10 mg once daily (maximum dose for mild-moderate disease) 1

For moderate to severe Alzheimer's disease:

  • Follow same initial titration (5 mg for 4-6 weeks, then 10 mg) 1
  • After at least 3 months on 10 mg daily, may consider increasing to 23 mg once daily 1
  • The 23 mg dose shows marginally higher rates of nausea (11.8% vs 3.4%) and vomiting (9.2% vs 2.5%) compared to 10 mg 1

Important Clinical Considerations

Expect modest benefits: Before starting treatment, counsel the patient and family that cholinesterase inhibitors provide modest improvement - approximately 20-35% of patients show a 7-point improvement on neuropsychologic tests, equivalent to delaying decline by about one year 2. This represents only a 5-15% benefit over placebo 2.

Common side effects to anticipate:

  • Nausea, vomiting, diarrhea (mild and usually transient) 2
  • Initial increase in agitation may occur but typically subsides after the first few weeks 2
  • Taking medication with food significantly reduces GI symptoms 2

Monitoring response:

  • Assessment requires 6 to 12 months of observation to determine benefit 2
  • Look for stabilization or delayed deterioration of cognitive/behavioral problems rather than dramatic improvement 2
  • Use physician global assessment, caregiver reports, or functional/behavioral changes - brief mental status tests are relatively insensitive 2

When to Discontinue

Stop donepezil if: 2

  • Side effects develop and do not resolve
  • Poor adherence
  • Deterioration continues at the pretreatment rate after 6-12 months of treatment

Important note: Patients who don't respond to one cholinesterase inhibitor may respond to another, so consider switching rather than abandoning this drug class entirely 2.

Safety Advantages

Donepezil has significant advantages over other cholinesterase inhibitors:

  • Not hepatotoxic - no liver monitoring required (unlike tacrine) 2
  • Once-daily dosing improves adherence 2
  • Generally well-tolerated with mild, transient adverse effects 2, 3

Practical Titration Tips

For the 78-year-old patient with worsening disease, if considering the higher 23 mg dose after adequate trial of 10 mg, use intermediate dose titration (alternating 10 mg and 23 mg on alternate days for 4 weeks, or using 15 mg for 4 weeks) before full escalation to reduce cholinergic side effects, particularly nausea 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.